Back to all Representative Matters
May 3, 2021
Small Pharma Completes $63 Million Brokered and Non-Brokered Private Placements, Qualifying Transaction and Initial Listing on the TSX Venture Exchange
On April 29, 2021, Small Pharma Inc. (TSXV: DMT) (formerly Unilock Capital Corp.) completed its acquisition of Small Pharma Ltd (“Small Pharma”), a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, and initial listing on the TSX Venture Exchange by way of a qualifying transaction under the TSXV Capital Pool Company program.
In connection with the reverse takeover, Small Pharma completed a broker led subscription receipt financing of $58 million and a non-brokered convertible note financing of $5 million.
Aird & Berlis acted as Canadian legal counsel to Small Pharma with a team that included Richard Kimel, Melanie Cole, Danny Kharazmi, Sean Green (Capital Markets), Emily Chittick and Al Turnbull (Articling Students).